EMV Capital announced the acquisition and investment into Wanda Inc, a San Francisco-based digital health company commercialising advanced clinical decision support software powered by machine learning and real time patient data analysis. EMV Capital’s investment will enable Wanda to accelerate its growth in the North American market, as well as to enter the UK and European markets. Wanda was founded from the results of eight clinical trials at the University of California Los Angeles (UCLA) with Distinguished Professor of Computer Science & Electrical Engineering Majid Sarrafzadeh being one of the co-founders.
“I’m excited to welcome Wanda, an innovative digital health company into the EMV Capital family” said Dr. IlianIliev managing director of EMV Capital. “Wanda has shown impact and strong traction in the past couple of years and we are excited to support the company’s team through its growth phase. It fits in our investment thesis of backing exciting AI-powered technology platforms that can scale rapidly through industry partnerships.”
Wanda is dedicated to advancing the effectiveness and efficiency of medicine by combining machine learning, virtual care and modern software applications to empower payers and providers to better manage the risk and outcomes of caring for patients with chronic diseases such as heart failure. Wanda’s predictive patient care platform is clinically proven to improved patients adherence and outcomes while dramatically lowering the cost of care. More information about Wanda can be found at http://www.yourwanda.com.
Dr. Sarrafzadeh is also co-founder and co-director of UCLA’s center for SMART Health and a co-director of BRITE center on Minority Health Disparities. His current research focus is Embedded Computing with emphasis in healthcare. Professor Sarrafzadeh has published more than 500 papers, co-authored 5 books, and is an inventor, patent holder and company founder.